



Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Sunao Manabe, Representative Director, President and CEO
(Code no.: 4568, Prime Market, Tokyo Stock Exchange)
Please address inquiries to Kentaro Asakura,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
<https://www.daiichisankyo.com>

Daiichi Sankyo Announces New President & COO

Tokyo, Japan - (January 31, 2023) – Daiichi Sankyo Company, Limited (hereinafter, the Company) today announced the appointment of a new President & COO effective as of April 1, 2023, which was resolved at the Board of Directors meeting held on January 31.

1. Reason for the appointment of new President & COO

We have positioned the first half of our current 5-year Business Plan (5YBP, FY2021-FY2025) as a period for investment to maximize the value of 3 ADCs and have actively invested in R&D, supply chain, and oncology business capabilities. We have made a very good progress in the 5YBP so far as we successfully launched ENHERTU[®] and expanded its indications. As a result, ENHERTU is rapidly gaining market share in countries and regions around the world. Our other ADCs are also showing promising data. In the latter half of the 5YBP, we are expecting to expand our oncology business globally and enter into a period of profit growth. To ensure that we will achieve the 5YBP, we need to enhance our management structure, and in particular the execution of our 5YBP strategies.

Meanwhile, the Company's Nomination Committee, which is an advisory body to the Board of Directors meeting, has been discussing the president's succession plan for several years. Based on the common "core values" and "core behaviors" of Daiichi Sankyo, the committee has defined the personnel requirements for the successor to the president and has intensively discussed the selection of the most suitable candidate in leading the mid- to long-term growth of the Company.

With the aim of enhancing management structure to further strengthen execution in order to successfully achieve the 5YBP and realize the 2030 vision, "Innovative Global Healthcare Company Contributing to the Sustainable Development of Society," a new Representative Director, President & COO, was today appointed at the Board of Directors meeting based on the recommendation of the Nomination Committee.

About Daiichi Sankyo

Daiichi Sankyo is dedicated to creating new modalities and innovative medicines by leveraging our world-class science and technology for our purpose “to contribute to the enrichment of quality of life around the world.” In addition to our current portfolio of medicines for cancer and cardiovascular disease, Daiichi Sankyo is primarily focused on developing novel therapies for people with cancer as well as other diseases with high unmet medical needs. With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 16,000 employees around the world draw upon a rich legacy of innovation to realize our 2030 Vision to become an “Innovative Global Healthcare Company Contributing to the Sustainable Development of Society.” For more information, please visit www.daiichisankyo.com.

Media Contacts:

Japan:

Koji Ogiwara

Daiichi Sankyo Co., Ltd.

ogiwara.koji.ay@daiichisankyo.co.jp

+81 3 6225 1126 (office)

Investor Relations Contact:

DaiichiSankyoIR@daiichisankyo.co.jp